C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-21 EST			5-day change	1st Jan Change
2.120 ^USD	-2.75%		-8.23%	+10.99%

12-02	TD Cowen Initiates C4 Therapeutics at Buy	MT
11-21	C4 Therapeutics Inc files for mixed shelf of up to $400 million - SEC filing	RE

C4 Therapeutics, Inc. Announces First Patient Dosed in CFT8919 Clinical Trial

Published on 11/06/2024 at 07:00 am EST

S&P Capital IQ

C4 THERAPEUTICS, INC.

-2.75%

BETTA PHARMACEUTICALS CO., LTD.

+1.01%

C4 Therapeutics, Inc. (C4T) announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in Greater China.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	C4 THERAPEUTICS, INC.	2.120USD	-2.75%	-8.23%	211M
	BETTA PHARMACEUTICALS CO., LTD.	48.77CNY	+1.01%	-4.43%	2.92B

Latest news about C4 Therapeutics, Inc.

12-02	TD Cowen Initiates C4 Therapeutics at Buy	MT
11-21	C4 Therapeutics Inc files for mixed shelf of up to $400 million - SEC filing	RE
11-21	C4 Therapeutics Files $400 Million Mixed Shelf	MT
11-06	C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	C4 Therapeutics Q3 revenue beats estimates	RE
25-10-16	C4 Therapeutics Prices $125 Million Underwritten Offering; Shares Fall Pre-Bell	MT
25-10-01	Investors left reading tea leaves
25-10-01	C4 Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma	CI
25-10-01	C4 Therapeutics Signs Clinical Trial Collaboration, Supply Deal With Pfizer	MT
25-10-01	C4 Therapeutics, Pfizer partner on trial combining Cemsidomide and elranatamab for relapsed/refractory multiple myeloma	RE
25-09-22	C4 Therapeutics, Inc. - Special Call
25-09-20	C4 Therapeutics presents cemsidomide phase 1 multiple myeloma data supporting potential best-in-class profile at the International Myeloma Society annual meeting	RE
25-09-20	C4 Therapeutics, Inc. Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-In-Class Profile at the International Myeloma Society Annual Meeting	CI
25-09-17	Barclays Initiates C4 Therapeutics at Overweight With $8 Price Target	MT
25-09-15	Stephens Upgrades C4 Therapeutics to Overweight From Equalweight, Adjusts Price Target to $6 From $3	MT
25-09-04	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration	CI
25-09-04	C4 Therapeutics Says Biogen's IND Application Accepted by FDA to Treat Autoimmune Diseases	MT
25-08-07	C4 Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 3000 Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Dynamic Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 3000E Value Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 3000E Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell Small Cap Completeness Index	CI
25-06-30	C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Value Index	CI

Chart C4 Therapeutics, Inc.

Duration

Period

CCCC: Dynamic Chart

Company Profile

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patientsâ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the bodyâs natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Employees

110

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company